Altium Capital Management LP Cerevel Therapeutics Holdings, Inc. Transaction History
Altium Capital Management LP
- $283 Million
- Q3 2024
A detailed history of Altium Capital Management LP transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Altium Capital Management LP holds 20,700 shares of CERE stock, worth $0. This represents 0.16% of its overall portfolio holdings.
Number of Shares
20,700Holding current value
$0% of portfolio
0.16%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding CERE
# of Institutions
8Shares Held
5.01MCall Options Held
3.3KPut Options Held
0-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
-
Segantii Capital Management LTD1.14MShares$05.99% of portfolio
-
Tekla Capital Management LLC176KShares$00.22% of portfolio
-
Credit Suisse Ag Zurich, V8112KShares$00.0% of portfolio
-
Kellner Capital, LLC New York, NY20.3KShares$01.55% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...